Status of hypoxia-inducible factor-1α expression in non-small cell lung cancer

• Published in: Pharmazie Vol. 76; no. 9; p. 404
• Main Authors: Li, Yangni, Zhang, Yishu, Li, Xuran, Huang, Yanfen, Chen, Weiyan, He, Lan, Zhang, Yuyan
• Format: Journal Article
• Language: English
• Published: Germany 01.09.2021
• Subjects: Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Cell Hypoxia; Cell Line, Tumor; Female; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit - genetics; Hypoxia-Inducible Factor 1, alpha Subunit - metabolism; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Lung Neoplasms - metabolism; Male; Prognosis
• ISSN: 0031-7144
• DOI: 10.1691/ph.2021.1524

According to the latest statistics from WHO for all cancers, lung cancer tops the list with a 14.5% prevalence and a 22% death rate in men, similar to the prevalence in women, which is 13.8%. It is also the number one killer of cancer in China, with 40 in every 100,000 people suffering from lung cancer. HIF-1α is widely present in human cells in hypoxic environments. It regulates the body's response to hypoxia, cell oxygen balance, and hypoxia gene expression; participates in the proliferation and apoptosis of non-small cell lung cancer cells; participates in the invasion, metastasis, and neovascularization of tumor tissues; and affects the treatment and prognosis of non-small cell lung cancer. In view of the role of HIF-1α in the occurrence and development of non-small cell lung cancer, blocking HIF-1α by use of a single medication or combination chemotherapy has become a research hotspot. This review summarizes the role of HIF-1α in non-small cell lung cancer and provides new ideas for the treatment of this cancer type by synthesizing the research results of various authors.